<DOC>
	<DOCNO>NCT01850628</DOCNO>
	<brief_summary>This study biospecimen discovery project serve pilot comprehensive 'omics approach use fresh core biopsy tissue blood sample DNA protein analysis , well pair tumor-normal exome DNA RNA sequencing .</brief_summary>
	<brief_title>NSABP Biospecimen Discovery Project</brief_title>
	<detailed_description>This study conduct select NSABP sit investigator willing give paclitaxel plus trastuzumab trastuzumab/pertuzumab-based combination initial component neoadjuvant therapy pilot comprehensive 'omics approach use next generation sequence protein expression post-translational modification analysis use mass spectrometry ( MS ) base Reverse Phase Protein Array-based proteomics . Tumor sample obtain baseline 48 72 hour initial drug treatment study variation biological response agent . The study tumor early first treatment probe biological response treatment rich source predictive biomarkers .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>The diagnosis invasive adenocarcinoma breast must make core needle biopsy limit incisional biopsy . The breast cancer must HER2positive base current ASCO/CAP ( American Society Clinical Oncology/College American Pathologists ) Guideline Recommendations Human Epidermal Growth Factor Receptor 2 Testing Breast Cancer . The patient must mass breast measure great equal 2.0 cm physical exam and/or ultrasound accessible safe repeat biopsy . Patients diagnosis inflammatory breast cancer eligible palpable detectable breast mass accessible safe repeat biopsy . Planned initial treatment combination paclitaxel trastuzumab trastuzumab/pertuzumabbased combination . Schedule paclitaxel/trastuzumab trastuzumab/pertuzumab administration per investigator . Excisional biopsy lumpectomy perform prior registration . Previous therapy chemotherapy target therapy malignancy . Treatment , include radiation therapy ( RT ) , chemotherapy , and/or target therapy , administer currently diagnose breast cancer prior registration . Other nonmalignant systemic disease would preclude patient receive chemotherapy target therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>National Surgical Adjuvant Breast Bowel Project ( NSABP )</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>pertuzumab</keyword>
	<keyword>HER2 positive ( human epidermal growth factor receptor 2 )</keyword>
	<keyword>Proteomics</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Anthracycline therapy</keyword>
	<keyword>Locally advanced</keyword>
	<keyword>Operable</keyword>
	<keyword>Biomarkers</keyword>
</DOC>